Scottsdale, Arizona 10/20/2009 3:44:13 AM
News / Finance

Wound Management Technologies Inc. (WNDM.OB) to Present Wound Care Product at Annual Clinical Symposium

QualityStocks would like to highlight Wound Management Technologies Inc. (OTCBB: WNDM). Wound Management Technologies, Inc., through its subsidiary Wound Care Innovations, markets and distributes wound care products to the healthcare market under patented technology licensed to the company. The company is positioned and seeks to be a leading provider of wound care products.

 

In the company’s news Friday,

 

Wound Management Technologies Inc. announced that its subsidiary, Wound Care Innovations, will present at the 24th Annual Clinical Symposium on Advances in Skin & Wound Care: The Conference for Prevention and Healing beginning October 22 in San Antonio, Texas.

 

Dr. Jane Fore MD, medical director of the Tri-State Wound Care and Hyperbaric Center in Clarkston, Wash., will present results of her clinical study of Wound Care Innovations’ CellerateRx, demonstrating its increased efficiency of healing skin tears and flaps. Dr. Fore will present the findings to more than 1,100 practitioners attending the conference.

 

“I am delighted to be presenting this abstract on the use of CellerateRx on skin tears and flaps. I have been using CellerateRx in my wound care protocols for over five years. It is an essential part of my successful wound care treatments. More of the regional nursing homes in my area are taking my skin tear protocol (CellerateRx) and are adapting it into their facilities due to the outcomes and cost effectiveness,” Dr. Fore stated in the press release.

 

According to the company, CellerateRx received FDA-approval for applications of acute and chronic wounds, including pressure ulcers (stages I-IV), traumatic wounds, diabetic ulcers, surgical wounds, venous stasis ulcers, ulcers due to arterial insufficiency, superficial wounds, and first and second degree burns.

 

Cathy Bradshaw, president of Wound Care Innovations, said CellerateRx’s efficiency is important for various applications and can address several medical needs.

 

“Skin tears represent a major problem in the elderly and compromised patients. Untreated skin tears can serve as a portal of entry for infection and be a source of pain for the patient. Their treatment can also have an impact on facilities’ resources. This evidence based abstract demonstrates that the use of CellerateRx is not only effective in the management of skin tears, but also very cost effective as well, as shown by resolution with only one application,” Bradshaw stated.

 

About QualityStocks

 

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

 

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.